Drug & intervention

valacyclovir

RxCUI 73645

Clinical trials20
Recruiting2
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Valaciclovir

Valaciclovir, also spelled valacyclovir, is an antiviral medication used to treat outbreaks of herpes simplex or herpes zoster (shingles). It is also used to prevent cytomegalovirus following a kidney transplant in high risk cases. It is taken by mouth. Common side effects include headache and vomiting. Severe side effects may include kidney problems. Use in pregnancy appears to be safe. It is a prodrug, which works after being converted to aciclovir in a person's body. Valaciclovir was patented in 1987 and came into medical use in 1995. Valaciclovir is a therapeutic alternative on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 98th most commonly prescribed medication in the United States, with more than 7 million prescriptions.

Read on Wikipedia ↗ Wikidata Q418594 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

20 shown
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)NCT07660094 · 2026-06-15
RECRUITING
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & SurgeryNCT03541928 · 2018-08-02
RECRUITING
Anti-viral Therapy in Alzheimer's DiseaseNCT03282916 · 2018-02-12
COMPLETED
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLCNCT03004183 · 2017-07-01
COMPLETED
Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal MelanomaNCT02831933 · 2017-02-15
TERMINATED
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)NCT02768363 · 2016-05-01
ACTIVE_NOT_RECRUITING
Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?NCT01176409 · 2010-09-01
COMPLETED
Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the CervixNCT00946556 · 2010-04-01
COMPLETED
Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?NCT00860977 · 2010-03-01
COMPLETED
Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected PersonsNCT01026454 · 2010-02-01
COMPLETED
An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative PersonsNCT01059084 · 2010-01-01
WITHDRAWN
Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and SheddingNCT00803543 · 2009-01-01
COMPLETED
HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and BreastfeedingNCT00530777 · 2008-04-01
COMPLETED
Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIVNCT00527618 · 2007-12-01
COMPLETED
Systematic Evaluation of Antiviral Medication in SchizophreniaNCT00514449 · 2007-06-01
COMPLETED
HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected PersonsNCT00465205 · 2005-01-01
COMPLETED
Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV SheddingNCT00158509 · 2004-08-01
COMPLETED
HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.NCT00378976 · 2003-08-01
COMPLETED
A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected PersonsNCT00161434 · 2003-03-01
COMPLETED
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell TransplantationNCT00045292 · 2002-04-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.